Second Sight Announces Positive Five-Year Data from Argus II Retinal Prosthesis System
| Printer friendly version
Second Sight announced in a press release the publication of positive results from a long-term clinical trial of the Argus II Retinal Prosthesis System. According to the press release, the five-year trial included 30 subjects who were blind due to retinitis pigmentosa (RP). The results, which will be published in Ophthalmology, indicate that the Argus II device provided improved visual function that was sustained over the course of the trial. The study further reported improved patient well-being and an acceptable safety profile. Will McGuire, President and CEO of Second Sight, said:
“We are excited to see that the substantial visual improvement gained from the Argus II endures over five years – promising news for patients blinded by RP, as well as for our company’s continued efforts to restore vision.”
The Argus II Retinal Prosthesis System assists wearers with RP-related blindness by capturing images using an eyeglass-mounted camera, converting the images to electrical pulses, and transmitting the electrical pulses to the retinal surface. The Argus II system received FDA approval in February 2013, and according to the press release a 2014 study supported the device’s long-term cost effectiveness.
Related
Jordan Gottdank
Jordan Gottdank is an associate in our San Diego office. His practice focuses on patent prosecution and litigation.
Mr. Gottdank earned his J.D. from UCLA School of Law, where he co-founded the Intellectual Property Law Association and worked as a research assistant in the fields of intellectual property law and international environmental regulation. While in law school, Mr. Gottdank served as a judicial extern for four judges in the U.S. District Court for the Central District of California, working exclusively on patent cases. He has experience in a wide range of fields, including electronics, communications technology, optics, medical devices, transportation, apparel, and sporting goods.
Mr. Gottdank worked as a summer associate at the firm in 2014 and joined the firm in 2015.
Click here to read full bio View all posts published by Jordan Gottdank »
By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.
Share